The aim of our study was to conduct a systematic review of studies evaluating antiviral
therapy with pegylated interferon (PEG-IFN) alfa in combination with ribavirin for the …

Hepatitis C virus (HCV) infection may lead to significant liver injury, and viral, environmental,
host, immunologic and genetic factors may contribute to the differences in the disease …

Background The hepatitis C virus (HCV) is a major public health problem and a leading
cause of chronic liver disease. 5 An estimated 180 million people are infected worldwide. 6 …

Pegylated interferon (pegIFN) and ribavirin eradicates hepatitis C virus (HCV) in one third of
liver recipients with recurrent disease. Side effects are frequent and potentially life …

A number of hepatotrophic viruses affect organ transplant candidates and recipients. The
most important agents causing acute and chronic hepatitis are hepatitis B virus (HBV), with …

Antiviral therapy after liver transplantation (LT) using interferon (IFN) and ribavirin (RBV) can
achieve a sustained virological response (SVR) rate ranging from 20% to 45%. The aims of …

“Occult” HCV infection has been defined as detection of HCV RNA in liver tissue alone or in
liver tissue as well as in peripheral blood mononuclear cells (PBMCs) despite constantly …

Antiviral therapy for the treatment of hepatitis C virus (HCV) infection is used before and after
liver transplantation. The objective of this study was to determine the most cost-effective …

Pegylated interferon with ribavirin (Peg/R) is the most effective therapy for chronic hepatitis
C virus (HCV) but its utility and effectiveness after liver transplantation has been difficult to …

Studies of boceprevir and telaprevir based antiviral therapy in liver transplant (LT) recipients
with hepatitis C genotype 1 infection have demonstrated dramatic increases in tacrolimus …